PharmaBoardroom

USA: 2 Things the Biden Administration can do Now to Lower Costs…

PhRMA’s Stephen J. Ubl outlines two ways in which the new US presidency can help lower healthcare costs and why biopharmaceutical companies support…

China: AstraZeneca/Junshi anti-PD-1 Tie-Up; New UK Biologics Plan…

The latest from Chinese pharma, including a new deal between AstraZeneca and Junshi Biosciences; Innoforce and dMed’s R&D collab; and investment…

Carl Firth – CEO, ASLAN Pharmaceuticals

ASLAN Pharmaceuticals is a clinical-stage immunology-focused biopharmaceutical company. CEO Dr Carl Firth reveals why the company has shifted its…

ISREC’s Susan Gasser: A “Hard-Nosed” Approach to Research…

After 15 years as director at the Friedrich Miescher Institute for Biomedical Research (FMI) (2004-2019) and even longer as the group leader at her…

Mexico: US Vaccine Tourism; CanSino Stepping Up; AMLO Calls for…

The latest from Mexico’s fight against COVID-19, including news of vaccine tourism into the US, how China’s CanSino is filling the gaps left by…

Marc-Olivier Geinoz – CEO, Dipharma SA

Dipharma SA is a Swiss specialty pharmaceutical company, developing improved generics medicines for rare metabolic diseases. Founder & CEO…

HSA: APAC’s Regulatory Gold Standard

As the most important pharma hub in its region, and one of the most important globally, many companies look to launch new products in Singapore first…

5 Things to Know about Saudi Arabian Pharma

A rundown of five things to know about the USD 8.2 billion Saudi pharma market, including the impact of ‘Vision 2030’, the country’s leading…

China: Yangtze River Pharmaceutical Group (YRPG) in Profile

One of the largest domestic pharma companies in China (ranking number one from 2014 to 2019), Yangtze River Pharmaceutical Group (YRPG) is so-named…

Choong May Ling, Mimi – CEO, Health Sciences Authority (HSA),…

Dr Choong May Ling, Mimi, CEO of Singapore’s Health Sciences Authority (HSA), one of the leading regulatory bodies in the Asia-Pacific region,…

Lorenzo Ambrosini – CEO, Agire Foundation, Switzerland

Lorenzo Ambrosini of the Agire Foundation introduces the major new innovation projects underway in the Italian-speaking Swiss canton of Ticino; the…

Medtech’s Post-COVID Paradigm in APAC

At USD 150 billion, Asia-Pacific is home to the world’s second largest medtech market and, with a CAGR of nine percent, certainly its most dynamic.…

Tagged with A